Cargando…

Drug combination therapies for SARS-CoV-2 (COVID-19) treatment

The COVID-19 pandemic has brought fear and havoc into the world in ways we have never imagined. More than 10 million people have been infected and more than 500,000 have died worldwide. Until now no definite cure has been discovered and no vaccine is yet available for its prevention. Efforts and res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dable-Tupas, Genevieve, Derecho, Cecile Melisse P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906121/ http://dx.doi.org/10.1016/B978-0-323-85156-5.00001-8

Ejemplares similares

Drug repurposing for SARS-CoV-2 (COVID-19) treatment
por: Mtewa, Andrew G., et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
por: Drożdżal, Sylwester, et al.
Publicado: (2021)

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
por: Drożdżal, Sylwester, et al.
Publicado: (2020)

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
por: Bobrowski, Tesia, et al.
Publicado: (2021)

Candidate drugs against SARS-CoV-2 and COVID-19
por: McKee, Dwight L., et al.
Publicado: (2020)

Executable network of SARS-CoV-2-host interaction predicts drug combination treatments
por: Howell, Rowan, et al.
Publicado: (2022)

Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)
por: Khodadadi, Ehsaneh, et al.
Publicado: (2020)

Identification of Drug Combination Therapies for SARS-CoV-2: A Molecular Dynamics Simulations Approach
por: Abdel-Halim, Heba, et al.
Publicado: (2022)

Developing drugs against essential proteins of SARS-CoV-2 for the treatment of COVID-19
por: Bajaj, Teena
Publicado: (2022)

Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
por: Wang, Xuanting, et al.
Publicado: (2021)

Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients
por: De Forni, Davide, et al.
Publicado: (2022)

Neurological Complications of SARS-CoV, MERS-CoV, and COVID-19
por: Alshebri, Munirah Saad, et al.
Publicado: (2020)

Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
por: Mahendiratta, Saniya, et al.
Publicado: (2021)

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing
por: Glebov, Oleg O.
Publicado: (2020)

Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
por: Abuo-Rahma, Gamal El-Din A., et al.
Publicado: (2020)

Prevalence Of Malnutrition In Adult Patients Diagnosed With SARS COV2 Pneumonia At A Private Tertiary Care Hospital In The Philippines
por: Tupas, M., et al.
Publicado: (2023)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

SARS-CoV-2 and COVID-19
por: Sheng, Wang-Huei, et al.
Publicado: (2020)

Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing
por: Krishnamoorthy, Pandikannan, et al.
Publicado: (2021)

Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?
por: Lai, Chih-Cheng, et al.
Publicado: (2020)

Trends in MERS-CoV, SARS-CoV, and SARS-CoV-2 (COVID-19) Diagnosis Strategies: A Patent Review
por: Nascimento Junior, José Adão Carvalho, et al.
Publicado: (2020)

Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease()
por: González-Castro, A., et al.
Publicado: (2022)

Pharmacological therapies and drug development targeting SARS-CoV-2 infection
por: Jiang, Yizhou, et al.
Publicado: (2022)

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
por: Bobrowski, Tesia, et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
por: Hwang, Yu-Chyi, et al.
Publicado: (2022)

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
por: Verma, Surjeet, et al.
Publicado: (2020)

Promising impacts of mesenchymal stem cell therapy in treatment of SARS-CoV-2 (COVID-19)
por: Khorshidi, Masoud, et al.
Publicado: (2020)

An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
por: Hillary, Varghese Edwin, et al.
Publicado: (2023)

Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review
por: Suhail, Shanzay, et al.
Publicado: (2020)

Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19
por: Bhati, Shipra
Publicado: (2020)

Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19
por: Cui, Wen, et al.
Publicado: (2020)

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
por: Poduri, Ramarao, et al.
Publicado: (2020)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)

Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19)
por: Al-Tawfiq, Jaffar A.
Publicado: (2020)

Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
por: Conway, Susan R., et al.
Publicado: (2022)

Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
por: Minenkova, Olga, et al.
Publicado: (2022)

Drug Discovery Strategies for SARS-CoV-2
por: Shyr, Zeenat A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c2t9lfe1dqv9a29jfhdur6rgl7